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PreviewsFoxp3 expression. A Foxo3 binding motif
is present in a proximal region of the
Foxp3 promoter and was shown to be
required for Foxp3 expression. Collec-
tively, these studies have revealed that
Foxo transcription factors promote the
transcription of the Foxp3 gene in iTregs
(Kerdiles et al., 2010; Harada et al.,
2010; Ouyang et al. 2010).
Regulation of Foxo transcriptional
activity is mainly dependent on the phos-
phorylation of the Foxo proteins via PI3K-
Akt pathway. Binding of growth factors to
their receptors initiates PI3K and Akt acti-
vation, followed by Foxo phosphorylation,
leading to inactivation of Foxos. The
mammalian target of rapamycin (mTOR)
is also one of the downstream targets of
Akt. Recent studies (Haxhinasto et al.,
2008; Sauer et al., 2008) have docu-
mented that mTOR forms the PI3K-Akt-
mTOR axis in regulating Foxp3 expres-
sion. The involvement of mTOR in the
differentiation of iTreg cells was further
supported by the finding that T cells lack-
ing mTOR kinase differentiate into iTreg
cells by TCR stimulation alone in the
absence of TGF-b. It is therefore plausible
that PI3K-Akt signaling might suppress
the Foxp3 expression via mTOR activa-
tion and Foxos inactivation.Collectively, the studies by Kerdiles
et al. and others strongly support the
notion that Foxo1 and Foxo3 have critical
overlapping roles in the development of
thymic-derived natural Treg and TGF-b-
induced iTreg cells. Kerdiles et al. (2009)
previously reported that Foxo1 regulates
the homeostasis and life span of naive
T cells. Yet it remains unclear how Foxos
play different roles when they are in naive
or Treg cells. Furthermore, several inter-
acting partners with Foxos have been
identified, whereas the mechanisms by
which Foxos regulate their target genes
in Treg cells still remain unknown. Recent
studies have shown that a functional
NFAT binding site lies in the Foxp3
enhancer region, with close proximity to
the Smad3 binding motif (Tone et al.,
2008), and the Runx transcription factors
are critically involved in induction and
suppressive function of Treg cells through
the direct binding to the Foxp3 gene
(Kitoh et al., 2009). Taken together, Treg
development via Foxp3 induction is a
complex event controlled by a variety of
transcription factors, including Foxo
family transcription factors. Further study
is required to decipher the complex tran-
scriptional network for regulating Foxp3
expression.Immunity 33, DREFERENCES
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Foxp3+ regulatory T cells can manifest functional ‘‘reprogramming’’ during inflammation. In this issue of
Immunity, Sharma et al. (2010) show how reprogramming is beneficial to CD8+ T cell immunity and how
the tumor microenvironment inhibits this process.Regulatory T (Treg) cells are key media-
tors in the control of immune responses
toward self- and non-self-antigens, and
suppression of excessive immune re-
sponses that can cause pathology in
the host (Wing and Sakaguchi, 2010; Pic-
cirillo et al., 2008). Treg cells develop as
a functionally specialized T cell subset inthe thymus and specifically express the
transcription factor Foxp3, a master
switch in Treg cell development (Hori
et al., 2003; Fontenot et al., 2005). Sus-
tained Foxp3 expression is required for
the genetic programming of Treg cell phe-
notype and suppressive function (Hori
et al., 2003; Fontenot et al., 2005; d’Hen-nezel et al., 2009). A developmental or
functional deficiency in Foxp3-expressing
Treg cells in mice and humans breaks
tolerance to self- and non-self -antigens
and provokes a spectrum of T cell-medi-
ated outcomes including multiorgan
autoimmunity, immunity to tumors and
microbes, and chronic inflammatoryecember 22, 2010 ª2010 Elsevier Inc. 837
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Previewsdisorders such as inflammatory bowel
disease (Wing and Sakaguchi, 2010;
Gavin et al., 2007).
Recent studies have established a de-
velopmental relationship between naive
CD4+ T cells and various Th cell subsets
and suggest a high degree of plasticity
enabling cells to switch from one lineage
to another and acquire distinct functional
profiles (Wing and Sakaguchi, 2010).
Inflammatory cues including cytokines
can particularly influence the expression
of Foxp3 in CD4+ T cells in turn influencing
Treg or Th17 cell fates respectively and
the type of immune response that will be
generated. For example, TGF-b1 and
IL-2 both favor the differentiation of
Foxp3+ Treg cells from naive T cells in
response to T cell activation in vitro,
whereas IL-6 abrogates this differentia-
tion; conversely, TGF-b1 together with
IL-6 favors Th17 cell differentiation.
Some Foxp3+ Treg cells can also be
induced from ‘‘Foxp3-less’’ T cells in the
periphery, as is the case in the gut where
potentially adverse immune responses to
dietary antigens or commensal microbes
must be suppressed (Wing and Sakagu-
chi, 2010; Piccirillo et al., 2008).
How do Foxp3+ Treg cells suppress or
favor the early phase of normal immune
responses depending on the context
in vivo? Recent studies suggest that
Foxp3+ Treg manifest a high degree of
functional plasticity. Under certain inflam-
matory settings, Foxp3+ Treg cells lose
their expression of Foxp3 and suppressor
phenotype, become functionally un-
stable, and ‘‘reprogram’’ or differentiate
into effector T (Teff) cells that secrete pro-
inflammatory cytokines. Whereas some
have suggested that Foxp3+ Treg cells
to be a stable population in vivo (Rubtsov
et al., 2010), other recent studies show
that Foxp3+ Treg cells can lose Foxp3
expression upon transfer into a lympho-
penic host, in course of an infection, or
in autoimmune inflammatory settings (Ko-
matsu et al., 2009; Zhou et al., 2009).
Natural and induced Foxp3+ T cell sub-
sets may vary in functional stability and
therefore in their susceptibility to conver-
sion. Thus, the plasticity of Foxp3+ Treg
cells to differentiate to Foxp3 Teff cells
is exquisitely controlled by several in-
trinsic (genetic) and extrinsic (inflamma-
tory) variables. This deconversion of
self-reactive Treg cells to Teff cells has
been viewed as potentially harmful to the838 Immunity 33, December 22, 2010 ª2010host, as the risk for autoimmunity could
increase.
In the current issue of Immunity,
Sharma et al. (2010) show that reprog-
rammed Treg cells play a physiologic
role in normal, protective immune re-
sponses. They show that reprogrammed
Foxp3+ Treg cells can favorably influence
the capacity of the primed host to mount
CD8+ T cell responses to a cross-pre-
sented antigen. Cross-presentation is a
process whereby the display of peptides
derived from extracellular environment
(exogenous antigens) on major histocom-
patibility complex (MHC) class I mole-
cules leads to the stimulation of effective
CD8+ T cell-mediated immune responses
to tumors and viral infections. Cross-
presentation is the primary pathway by
which the immune system, particularly
through the activity of professional APCs
such as dendritic cells (DCs) can detect
and respond to viral infections or tumor
antigens. Moreover, this cross-presenta-
tion pathway is most active under condi-
tions of Toll-like receptor (TLR) activation.
By means of a well-established oval-
bumin (OVA) vaccination model in Foxp3-
tagged reporter mice, Sharma et al. (2010)
show that conventional CD4+ Teff cells
that do not express Foxp3 and possess
no intrinsic regulatory function could pro-
vide help unless they were preactivated or
originated from preimmunized mice. Un-
expectedly, reprogrammed Foxp3+ Treg
cells were specifically needed to promote
the early cross-priming of CD8+ T cells
in vivo. In fact, reprogrammed Foxp3+
Treg cells provided most, if not all, of the
T helper cell activity to support initial
cross-presentation to CD8+ T cells in
mice never exposed to the antigen
in vivo (Figure 1). In such a system,
Foxp3+ Treg cells were rapidly activated
in vaccinated sites (within hours after
vaccination), and functional reprogram-
ming could be driven by CpG-induced,
MyD88-dependent IL-6 production, prob-
ably by DC. These results suggest that
reprogrammed Foxp3+ Treg cells are a
prominent functional consequence of
innate inflammatory cascades and repre-
sent a key mediator in the immune versus
tolerance decision checkpoint. These
observations are consistent with earlier
studies showing that IL-6, a product of
TLR signals, can deactivate the suppres-
sive function and drive Treg cell decon-
version of Foxp3+ Treg cells in vitro.Elsevier Inc.Sharma et al. (2010) make use of a
highly immunosuppressive B16 tumor
model in mice to show that reprog-
rammed Foxp3+ Treg cells play an impor-
tant functional role in antitumor immunity.
In this model, they make the observation
that the Foxp3+ Treg reprogramming
process in established tumors is promi-
nently inhibited and one of the main
reasons for the failure of therapeutic im-
munization. The authors in this study
also show that Treg reprogramming can
be regulated in vitro by the enzyme indo-
leamine 2,3-dioxygenase (IDO), an innate
immunoregulatory mechanism that par-
ticipates in immunosuppression in various
contexts, and typically induced by tumors
(Figure 1). Mice with established tumors
have substantially increased amounts of
IDO in tumor-draining lymph nodes, and
tumor-induced IDO can directly activate
Foxp3+ Treg cells for enhanced sup-
pressor activity. Conversely, when IDO
activity is blocked with 1-methyl-trypto-
phan, a potent IDO-inhibitor, then Treg
cells become unstable in tumor-bearing
hosts and are driven by inflammation to
undergo reprogramming into Th17 cells.
Sharma et al. (2010) also established
the local production of IL-6 as a central
inflammatory signal that forces the re-
programming of Foxp3+ Treg cells into
Teff cell, a feature not seen in Il6/ mice
(Figure 1). Previous studies show that
DC-derived IL-6 production can be di-
rectly suppressed by IDO via IDO-in-
duced activation of the GCN2 pathway
in DC. GCN2 was previously shown to
be an important pathway by which IDO
enhances Foxp3+ Treg cell-mediated
suppression while inhibiting Th17-lineage
differentiation. Here, they show that IDO
can act directly on the Foxp3+ Treg cells
to inhibit reprogramming via activation of
the endogenous GCN2 pathway. Thus,
IDO inhibits Treg reprogramming with
two pathways: by suppressing IL-6 pro-
duction indirectly in DC and directly via
the GCN2 pathway in Foxp3+ Treg cells.
Moreover, Sharma et al. (2010) showed
that in established B16 tumors, the IDO-
GCN2 pathway dominantly inhibited
Treg cell reprogramming after vaccina-
tion, and such inhibition served as a major
mechanism to disable the priming of anti-
tumor CD8+ T cells by vaccination (Fig-
ure 1). Although the abrogation of Treg
cell reprogramming was not absolute in it-










or Th17 cell phenotype






Figure 1. Functional Reprogramming
of Foxp3+ Treg Cells in Tumors
Whereas the thymus generates a subpopulation of
Foxp3+ natural Treg cells, naive CD4+ T cells can
also differentiate into Foxp3+ Treg cells after
T cell activation in the presence of appropriate
cytokines in the periphery. Sharma et al. (2010)
show that the IDO-GCN2 pathway dominantly
inhibits Treg cell reprogramming after vaccination
to a cross-presented antigen, and such inhibition
serves as a major mechanism to disable the
priming of antitumor CD8+ T cells by vaccination.
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Previewsamong differ tumor types, IDO-induced
suppression of Treg cell reprogramming
nonetheless is an important checkpoint
in the establishment of tumor immunity.
These studies suggest that one possible
avenue for therapeutic intervention that
may be more beneficial to the host may
be to destabilize or reprogram Treg cells
directly in tumors moreso that mere phys-
ical depletion.
Sharma et al. (2010) also show that
reprogrammed Foxp3+ Treg cells readily
upregulate CD40L expression, and this
upregulation is a requisite signal to enable
competent Th cell activity given that the
protective effect is abrogated in Cd40l/(CD40L-deficient) hosts. These results
suggest that the acquisition of CD40L
expression is a mechanistic intermediate
connecting vaccine-induced inflamma-
tion with CD40-mediated licensing of
DCs. Although these studies were con-
ducted with a CpG-based vaccine, it is
potentially envisaged that these observa-
tions are also recapitulated in any physio-
logical context in which a new antigen is
encountered in the absence of a large,
pre-existing pool of antigen-specific con-
ventional Th cells. Under such immuno-
logical circumstances, it is hypothesized
that unstable Foxp3+ Treg cells that are
reprogrammed after Foxp3 downregula-
tion constitute an important pool of
pre-existent Th cells with substantial
inflammatory potential. As such, how do
Th-dependent CD8+ immune responses
ever get started? The initial presentation
of helper-dependent antigens to CD8+
T cells depends on the availability of
antigen-specific CD4+ T cells from the
get-go in order to license the DCs for
subsequent CD8+ T cell activation. How-
ever, an important caveat to this model
is the exceptionally low precursor fre-
quency of naive CD4+ cells specific for
any new antigen in the exposed host. In
such cases, detection of optimal CD8+
T cell clonal activation and expansion
requires several days in vivo. Thus, this
begs the important question: where do
Th come from to enable such helper-
dependent, antigen-specific CD8+ T cell
responses? Sharma et al. (2010) show
that a substantial proportion of Foxp3+
Treg cells become unstable in response
to innate inflammation, poising them to
readily undergo rapid reprogramming
into inflammatory Teff cells and in turn
providing the requisite help for the initial
CD8+ T cells responses to a new antigen.
Thus, although normal CD4+ Th cells may
be sufficient to provide help in many
immune circumstances, deconverted
Treg cells play a critical role as Th cells
in unique circumstances in which a new
antigen is encountered by a naive host.
Collectively, these studies enable us to
rethink the mechanisms that dictate the
balance between tumor-induced sup-Immunity 33, Dpression and effective antitumor immu-
nity. Several questions still remain
unanswered: what is the antigen-specific
TCR repertoire of stable and unstable
Foxp3+ Treg cells? Do deconverting
natural versus induced Treg cells differ in
their genetic makeup, phenotype, and
respective capacity to drive these re-
sponses? What are the specific homing
and adhesion signals that favor the
recruitment and retention of deconverted
Treg cells in inflammatory sites? Are there
distinct DC subpopulations that are more
amenable to receiving help from reprog-
rammed Treg cells when mounting these
responses? Further studies are indeed
required to fully understand the molecular
basis for the functional plasticity and
stability of Treg and will undeniably facili-
tate safe and effective control of physio-
logical and inflammatory responses.REFERENCES
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